EAGLE PHARMACEUTICALS, INC. 4
4 · EAGLE PHARMACEUTICALS, INC. · Filed Feb 20, 2014
Insider Transaction Report
Form 4
FLAUM SANDER A
Director
Transactions
- Conversion
Common Stock, $0.001 par value
2014-02-18+8,572→ 26,512 total - Conversion
Common Stock, $0.001 par value
2014-02-18+2,887→ 29,399 total - Conversion
Common Stock, $0.001 par value
2014-02-18+8,580→ 17,940 total - Conversion
Series B Convertible Preferred Stock
2014-02-18−8,580→ 0 total→ Common Stock (8,580 underlying) - Conversion
Series B-1 Convertible Preferred Stock
2014-02-18−8,572→ 0 total→ Common Stock (8,572 underlying) - Conversion
Series C Convertible Preferred Stock
2014-02-18−2,887→ 0 total→ Common Stock (2,887 underlying)
Footnotes (3)
- [F1]Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series C Convertible Preferred stock automatically converted into one share of the Issuer's Common Stock on a 6.41-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.
- [F2]Reflects a 1-for-6.41 reverse stock split, pursuant to which each share of preferred stock became convertible into 1/6.41 of a share of common stock.
- [F3]The expiration date is not relevant to the conversion of these securities.